In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to… Read More »The Ins & Outs of Gene Therapy Drug Development: an interview with NMIN’s Scientific Director

Research by NMIN research leader Dr. Marcel Bally and team at Cuprous Pharmaceuticals is featured on the cover of the February 2020 issue of Drug Delivery and Translational Research. The… Read More »NMIN research leader’s finding selected as journal’s feature article

On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR).… Read More »“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology

On August 21, 2019, the Board of Directors approved NMIN’s initial investments of $4.3M in nanomedicines research. Over a two-year period, NMIN will support 20 innovative projects led by Canadian… Read More »NMIN releases first round of Research Investment

Over 100 delegates—researchers, trainees, partner organization representatives and other stakeholders—gathered at the Sheraton Vancouver Wall Centre in Vancouver, British Columbia, on September 13-14, 2019, to take part in NMIN’s first… Read More »NMIN holds its first Scientific Meeting

UBC attracts over $40M to host Networks of Centres of Excellence in nanomedicines Apr 16, 2019 – The NanoMedicines Innovation Network (NMIN) has been awarded $18.5 million in new funding… Read More »NMIN receives funding from NCE Program